Chie‐Schin Shih

Inactivation of the p53 pathway in retinoblastoma

Nikia A. Laurie, Stacy L. Donovan, Chie‐Schin Shih et al. · Nature · 2006 · 587 citations

Life Sciences, Genetics, Molecular Biology +12

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

Yelena Y. Janjigian, Akihito Kawazoe, Yuxian Bai et al. · The Lancet · 2023 · 467 citations

Medicine, Oncology, Pharmacology +17

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

Joseph Chao, Charles S. Fuchs, Kohei Shitara et al. · JAMA Oncology · 2021 · 443 citations · Full text

Medicine, Oncology, Gastrointestinal Oncology +12

Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries

Lindsey M. Hoffman, Sophie E. M. Veldhuijzen van Zanten, Niclas Colditz et al. · Journal of Clinical Oncology · 2018 · 435 citations · Full text

Medicine, Oncology, Pediatrics +15

Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study

Kohei Shitara, Sun Young Rha, Lucjan Wyrwicz et al. · The Lancet Oncology · 2023 · 339 citations

Medicine, Oncology, Pharmacology +16